Throat cancer is curable, especially when caught early. For cancers on or near the vocal cords that haven’t spread beyond their original site, the five-year survival rate reaches 85%. Even in more advanced cases, a combination of surgery, radiation, and sometimes chemotherapy can eliminate the disease, though the odds decrease as the cancer spreads further from where it started.
“Cure” in cancer medicine is a careful word. Doctors typically consider a patient cured when they remain in complete remission for five years or more, meaning no detectable cancer remains. But because stray cancer cells can sometimes linger undetected, most oncologists will phrase it as “no signs of cancer at this time” rather than making an absolute guarantee. For practical purposes, reaching five years cancer-free is the milestone that matters most, since the vast majority of recurrences happen within that window.
Survival Rates by Location and Stage
“Throat cancer” actually covers several distinct locations, and where the tumor grows has a major impact on how curable it is. The numbers below represent the percentage of patients alive five years after diagnosis, based on data from people diagnosed between 2015 and 2021.
Cancer on the vocal cords (glottis) has the best outlook. When it’s still localized, the five-year survival rate is 85%. Even when it has spread to nearby tissues or lymph nodes (regional), that rate is 56%. When it has reached distant parts of the body, 48% of patients still survive five years. The overall rate across all stages is 78%, largely because vocal cord cancers tend to cause hoarseness early, prompting people to seek help before the disease advances.
Cancer above the vocal cords (supraglottis) or below them (subglottis) is harder to detect early because symptoms are subtler. Localized supraglottic cancer has a 60% five-year survival rate, dropping to 48% for regional spread and 30% for distant spread. Subglottic cancers follow a similar pattern: 60% localized, 50% regional, 45% distant.
Hypopharyngeal cancer, which forms in the lower part of the throat behind the voice box, carries the toughest prognosis. Its five-year survival rate is 61% when localized but drops to 36% for regional disease and 20% when it has spread distantly. The overall rate across all stages is 35%, partly because this type rarely causes obvious symptoms until it’s more advanced.
Why HPV Status Changes Everything
One of the biggest factors in whether a throat cancer is curable has nothing to do with the treatment you receive. It’s whether the tumor is linked to the human papillomavirus (HPV). About 64% of oropharyngeal cancers (those in the tonsils and base of the tongue) test positive for HPV, and these patients do dramatically better than those whose cancers are caused primarily by smoking and alcohol.
Patients with HPV-positive oropharyngeal cancer have a three-year overall survival rate of 82%, compared to 57% for HPV-negative patients. That translates to a 58% lower risk of dying from the disease after adjusting for age, tumor size, and other factors. HPV-positive tumors are also less likely to recur locally (14% at three years versus 35% for HPV-negative tumors) and less likely to lead to a second primary cancer developing elsewhere.
In one study of patients treated with transoral laser microsurgery, those with HPV-positive disease had a five-year overall survival of 91% and a disease-specific survival of 95%. HPV-negative patients in the same study had a five-year overall survival of just 40%. This gap is one of the most significant discoveries in head and neck cancer over the past two decades, and it has reshaped how doctors approach treatment planning.
How Early-Stage Throat Cancer Is Treated
For small cancers confined to their original site, treatment is often highly effective and can preserve your ability to speak and swallow. Two main approaches dominate: radiation therapy and minimally invasive surgery.
Radiation alone cures a high percentage of early vocal cord cancers. For the smallest tumors (classified as T1a), five-year local control reaches 94%. Slightly larger tumors on both vocal cords (T1b) see 83% control, and moderate-sized tumors (T2a) reach 87%. These numbers reflect tumors controlled at the original site, meaning they didn’t grow back where they started. Laser surgery through the mouth achieves similar control rates for these early cancers, with no meaningful difference in survival. Radiation tends to produce slightly better voice quality afterward, but it costs more and takes longer.
For oropharyngeal cancers, robotic surgery through the mouth (known as TORS) has become a standard option. In a study of 184 patients with HPV-positive oropharyngeal cancer treated this way, the disease-specific survival rate was 98.6% at three years and 94.4% at five years. This approach has proven as effective as radiation with or without chemotherapy for early-stage HPV-related disease, and it often allows patients to avoid some of the long-term side effects of radiation.
Modern radiation techniques can also target throat tumors with remarkable precision. Across multiple studies of intensity-modulated radiation therapy for oropharyngeal cancers, local control rates consistently fell between 87% and 98% at two to four years. For laryngeal and hypopharyngeal cancers, the rates ranged from 77% to 90% at two years.
Advanced Throat Cancer and Combined Treatment
When throat cancer has spread to nearby lymph nodes or grown into surrounding tissues, treatment typically combines two or three approaches. The most common combination is radiation delivered alongside chemotherapy, which works better together than either alone. Some patients undergo surgery first, followed by radiation or chemoradiation depending on what the pathology reveals about the tumor’s aggressiveness.
The goal with advanced disease is still cure, not just symptom control. Many patients with regional spread do achieve long-term remission, though the road is harder. Treatment courses are longer, side effects are more significant, and recovery takes more time. For cancers that have spread to distant organs, treatment shifts toward extending life and managing symptoms, though even here some patients respond well enough to reach long-term survival.
Recurrence: When Cancer Comes Back
Even after successful treatment, throat cancer can return. The risk is highest in the first three years. In one study of HPV-positive oropharyngeal cancer patients treated with robotic surgery, about 11% experienced a local or regional recurrence, and 80% of those recurrences happened within the first three years after treatment.
For oral and oropharyngeal cancers more broadly, early-stage cases show recurrence rates of 25 to 30%, while advanced cases recur 50 to 60% of the time. This is a major reason why follow-up appointments, imaging, and physical exams continue for years after treatment ends. Most oncology teams schedule visits every one to three months in the first two years, gradually spacing them out as the risk decreases.
If the cancer does come back, it can sometimes still be treated curably, particularly if the recurrence is caught small and in a location that allows surgery or re-irradiation.
Life After Treatment
Being cured of throat cancer doesn’t always mean returning to exactly how things were before. The throat is involved in swallowing, speaking, and breathing, so treatment in this area can affect daily functions that most people take for granted.
Swallowing problems are the most common lasting issue. In a UK study of 152 head and neck cancer survivors, about half experienced some degree of swallowing difficulty after treatment. Most of those problems showed up in the first year. By years four and five, about 36% of those who initially had trouble still reported ongoing symptoms, translating to a long-term swallowing dysfunction rate of 18% across all patients studied. The permanent feeding tube rate in patients treated with minimally invasive surgery was notably lower, at 1.5% in one study of oropharyngeal cancer patients.
Voice changes are common after treatment for cancers on or near the vocal cords, ranging from mild hoarseness to more significant alterations in pitch and volume. Speech therapy helps many patients regain functional voice quality, though the timeline varies from weeks to months. Dry mouth from radiation, changes in taste, and neck stiffness are other side effects that can persist but generally improve over time with rehabilitation.
The practical reality is that most throat cancer survivors return to work, eat regular meals, and communicate normally, though some need ongoing speech or swallowing therapy to get there. The specific side effects depend heavily on where the tumor was located, what treatment was used, and how advanced the cancer was at diagnosis.